Resultados prometedores de la terapia génica para la acromatopsia

by DBGen Ocular Genomics

4 years ago
visión en color, terapia génica, acromatopsia

La acromatopsia es una enfermedad que afecta a una de cada 30.000 personas y se caracteriza por la ausencia parcial o total de la visión en color debida a la falta de función de un tipo de células ...

Progress in anti-VEGF gene therapy for age-related macular degeneration

by DBGen Ocular Genomics

4 years ago
retina, vision, gene therapy, ADM, Regenxbio, Adverum Biotechnologies

Macular degeneration, Age-related macular degeneration, Gene Therapy

Direct reprogramming of skin cells into photoreceptors in mice

by DBGen Ocular Genomics

4 years ago
retinal dystrophies, cells, vision, gene therapies

The end result of many retinal dystrophies is photoreceptor cell death and the irreversible loss of vision. To prevent the progressive loss of retinal neurons, and to slow down or reverse the progress...

Advances in gene therapy for retinitis pigmentosa due to RPGR gene mutation

by DBGen Ocular Genomics

4 years ago
Retinal Dystrophy, Retinitis pigmentosa, Gene Therapy

In the first months of 2020, positive results in gene therapy of X-linked retinitis pigmentosa (XLRP) have been reported. XLRP is an inherited genetic disorder that causes progressive vision loss, mai...

A third of the world’s population carries mutations associated with retinal dystrophies

by DBGen Ocular Genomics

4 years ago
mutations, retinal dystrophies, personalized medicine

A very recent study published in the scientific journal PNAS highlights an estimate, on a global scale, of the frequency of individuals carrying pathogenic mutations responsible for inherited re...

La metodología revolucionaria de edición génica CRISPR aplicada por primera vez a un paciente con una patología de la visión

by DBGen Ocular Genomics

4 years ago
amaurosis congénita, ceguera, edición génica CRISPR, visión, Editas Medicine

El paciente, tratado en el Casey Eye Institute, de la Oregon Health & Science University, forma parte de un grupo de 18 personas con amaurosis congénita de Leber que participan en el estudio BRILL...

First gene therapy application of Luxturna in the UK

by DBGen Ocular Genomics

4 years ago
gene therapy, Luxturna, UK, LCA, RPE, Spark Therapeutics

LCA is a childhood-onset severe retinal dystrophy, which causes irreversible blindness for which, until now, no treatment was available

DBGen’s genetic diagnosis of hereditary eye diseases tops the 1,000 patients figure

by DBGen Ocular Genomics

4 years ago
DBGen Ocular Genomics, genetic diagnoses, visual disorders, hereditary

We are glad to announce that early this year DBGen Ocular Genomics has achieved more than 1,000 genetic diagnoses of hereditary visual disorders.

Nueva herramienta de edición genómica de gran precisión para corregir enfermedades genéticas

by DBGen Ocular Genomics

5 years ago
prime editing, LCA, genómica, terapias

En los últimos años, se ha desarrollado una potente tecnología, llamada CRISPR-Cas9, para poder modificar el genoma de un organismo.

World Sight Day to raise awareness of blindness and visual impairment

by DBGen Ocular Genomics

5 years ago
view, child blindness, visual deficiency, ophthalmology

World Sight Day is observed annually on the second Thursday of October. This global event coordinated by The International Agency for the Promotion of Blindness (IAPB) in cooperation with the World He...

New gene therapy for autosomal dominant retinitis pigmentosa

by DBGen Ocular Genomics

5 years ago
gene therapy, retinitis, drug, dystrophy

The United States Food and Drug Administration (FDA) has just approved the designation of the QR-1123 therapy by the Dutch company ProQR as a new investigational drug. This drug aims to treat a form o...

DBGen presents a research optimizing the genetic diagnosis of color vision deficiency

by DBGen Ocular Genomics

5 years ago
vision, color, genetic, retina

DBGen is committed to the quality of genetic diagnosis and its major goal since the beginning of the company is to remain at the forefront of innovation, prioritize resolution of difficult cases, and ...